Morning Research: Johnson & Johnson, Mylan, Array BioPharma, and Brookdale Senior Living

LONDON, July 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday, July 23, 2013, shares in healthcare companies ended on a mixed note, tracking the broader market. The major movers in the sector included Johnson & Johnson (NYSE: JNJ), Mylan Inc. (NASDAQ: MYL), Array Biopharma Inc. (NASDAQ: ARRY), and Brookdale Senior Living Inc. (NYSE: BKD). has released full comprehensive research on JNJ, MYL, ARRY, and BKD. These free technical analyses can be downloaded by signing up at:  

Shares in Johnson & Johnson edged higher on Tuesday, extending their gains from previous trading sessions. The company's shares hit a 52-week high of $92.86 before finishing the day 0.15% higher at $92.42. A total of 8.47 million shares were traded which is below the daily average volume of 10.01 million. Johnson & Johnson's shares gained 2.50% in the last three trading sessions and 11.08% in the last one month as compared to a gain of 0.18% and 6.28% in the S&P 500 during the respective periods. Download free report on JNJ upon registration at:

Mylan Inc.'s stock slipped on Tuesday, reversing most of its recent gains. The company's shares oscillated between $32.15 and $32.75 before closing the day 1.01% lower at $32.32. A total of 3.82 million shares were traded which is slightly above the daily average volume of 3.81 million. The company's stock has gained 0.06% in the last three trading sessions, and it is currently trading near its 52-week high of $33.07. MYL technical report can be accessed for free by signing up at:

Shares in Array Biopharma Inc. surged on Tuesday, hitting a 52-week high of $6.64. The company's shares ended the session 10.43% higher at $6.14. A total of 11.36 million shares were traded which is above the daily average volume of 1.42 million. The stock has gained 13.08% in the last three trading and 22.68% in the last one month, thus outperforming the S&P 500 during the respective periods. The free report on ARRY can be downloaded by signing up now at:

Brookdale Senior Living Inc.'s stock fell sharply on Tuesday, finishing at $28.93, down 2.13% from its previous closing price. The company's shares oscillated between $28.83 and $29.62. A total of 1.02 million shares were traded which is below the daily average volume of 1.10 million. Despite Tuesday's pullback, Brookdale Senior Living's shares are trading near their 52-week high of $30.34, and also above their 50-day and 200-day moving averages. A free report on BKD can be accessed by registering at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.